Telix Makes $2.35 Billion Bet on ITM to Build a Global Powerhouse in Cancer Radiopharmaceuticals 

Telix Pharmaceuticals has agreed to merge with Germany’s ITM Isotope Technologies Munich in a transaction potentially worth $2.35 billion, a major expansion designed to strengthen Telix’s position in the rapidly growing market for radioactive medicines used to diagnose and treat cancer.

The combination brings together two complementary businesses.

Australia-based Telix develops radiopharmaceuticals for cancer imaging and treatment, while ITM is a major producer of the radioactive isotopes required to manufacture many of these medicines.

Radiopharmaceuticals combine radioactive isotopes with molecules designed to seek out specific biological targets. This allows radiation to be delivered directly to cancer cells while limiting exposure to surrounding healthy tissue.

Under the agreement, Telix will acquire 100% of ITM for an upfront enterprise value of $1.65 billion on a cash-free, debt-free basis.

After adjustments, ITM shareholders are expected to receive approximately $1.25 billion in Telix shares, while Telix will assume roughly $302 million of ITM’s net debt.

An additional $700 million could be paid if ITM achieves specified regulatory and commercial milestones associated with its experimental cancer therapy ITM-11.

The strategic importance of ITM extends well beyond a single drug.

The German company produces several isotopes increasingly important to targeted cancer treatments, including lutetium-177, actinium-225 and terbium-161. It also operates a global distribution network reaching more than 65 countries.

ITM generated approximately $273 million in revenue during 2025, with revenue growing at a compound annual rate of about 40% between 2021 and 2025.

For Telix, acquiring this infrastructure could provide significantly greater control over its supply chain.

Manufacturing radiopharmaceuticals is unusually complicated because radioactive isotopes decay rapidly and must often be produced, processed and transported to hospitals within strict time limits. Reliable access to isotopes is therefore a critical competitive advantage.

ITM would give Telix greater control over that process while reducing its dependence on outside suppliers.

The transaction also strengthens Telix’s drug-development pipeline.

ITM’s most advanced candidate, ITM-11, uses lutetium-177 to target gastroenteropancreatic neuroendocrine tumors, or GEP-NETs.

The therapy has successfully completed the Phase 3 COMPETE study, while another Phase 3 trial, COMPOSE, is fully enrolled and expected to produce an interim analysis during the first half of 2027.

If approved, ITM-11 could accelerate Telix’s expansion from diagnostic imaging into the commercial market for targeted radionuclide cancer therapies.

Management estimates that the combined company would generate more than $1.3 billion in pro forma revenue and income during 2026. Telix also expects manufacturing growth, cost reductions and other synergies to support a positive EBITDA contribution from the transaction beginning in 2027.

Investors nevertheless face several uncertainties.

The $700 million in additional consideration depends on ITM-11 achieving regulatory approvals and sales targets, meaning the full $2.35 billion price is not guaranteed.

The transaction also requires approval from Telix shareholders and regulators. Telix expects to hold an extraordinary shareholder meeting in November 2026, with completion targeted before the end of the year.

If completed, existing Telix shareholders would own approximately 76.3% of the combined company, while ITM shareholders would control about 23.7%.

The merger reflects growing competition surrounding nuclear medicine as pharmaceutical companies search for cancer treatments capable of delivering radiation with greater precision.

For Telix, the deal represents more than an acquisition of another biotechnology pipeline. It is an attempt to control the entire radiopharmaceutical chain—from producing critical isotopes to developing medicines, manufacturing them and ultimately delivering them to patients worldwide.

By combining Telix’s commercial and drug-development capabilities with ITM’s isotope infrastructure and cancer pipeline, the companies are betting that vertical integration will become a decisive advantage in one of oncology’s fastest-growing fields.